Trial Profile

Phase 1a initial single dose study of AV-101 in healthy volunters

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 02 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AV 101 (Primary) ; Imatinib
Indications Neuropathic pain
Focus Adverse reactions

Most Recent Events

29 Mar 2023 According to Aerovate media release, trial data published in ERJ Open Research and presented at the American Thoracic Society (ATS) International Conference in May.
22 Jun 2017 Results from this trial published in a VistaGen Therapeutics Media Release.
22 Jun 2017 According to a VistaGen Therapeutics media release, results from this study published in the Scandinavian Journal of Pain.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com